Clinical Trials Should Deal With Reimbursement Concerns Sooner: Study

September 21, 2012

Drugmakers’ health economics and outcomes research teams must provide earlier input on clinical trials so the data generated have a better chance of ensuring reimbursement for treatments after approval, according to a new study.

As more payers in the U.S. and EU look to comparative-effectiveness research to find new products worthy of reimbursement, drug companies with successful health economics teams are using them earlier on — such as during Phase III — to increase their reimbursement odds and justify their pricing schemes, according to the study from consulting firm Cutting Edge Information.

Among the top 20 pharmaceutical companies surveyed, 15 percent of the health economics teams’ time was devoted to helping clinical trials. For companies outside the top 50, only 2 percent were devoted to trials.

Clinical trial sponsors must stay abreast of current trends at home and abroad, or else face sizeable costs and possible warnings from the FDA or other regulatory agencies. If you’re a sponsor, a subscription to Clinical Trials Advisor would be in your best interest at keeping ahead of the changing industry.

Clinical Trials Advisor helps clinical research sponsors and clinical sites researching drugs and medical devices gain new business, improve operations and keep in compliance with the FDA’s GCP requirements. In every biweekly issue, you get practical advice on maximizing your clinical investments, updates on the latest regulatory and international news, reporting and training applicable to clinical trials, and more. Plus, it provides links to important documents from the FDA and international organizations, such as guidances, warning letters, Form 483s, and more. Subscribe today!